Copyright
©The Author(s) 2021.
World J Gastroenterol. Mar 14, 2021; 27(10): 976-989
Published online Mar 14, 2021. doi: 10.3748/wjg.v27.i10.976
Published online Mar 14, 2021. doi: 10.3748/wjg.v27.i10.976
Figure 1 Summary of treatment predominant flow by line of therapy.
SSA: Somatostatin analogues; PRRT: Peptide receptor radionuclide therapy; Liver embol: Liver embolization; HD-SSA: High-dose of somatostatin analogues.
- Citation: Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordoa T. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. World J Gastroenterol 2021; 27(10): 976-989
- URL: https://www.wjgnet.com/1007-9327/full/v27/i10/976.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i10.976